MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: the eagle who wrote (683)	2/17/1998 8:00:00 PM
From: seminole	of 1826

eagle <<< one thing that i think is very significant is that nci interest in this new drug. i understand that nci does not even get involved unless it is a very promising drug. could someone comment>>> The NCI's involvement is very significant. I believe their funding resulted from their own in house appraisal of MGI 114. The NCI originally rejected Illudin S, years earlier, due to its high toxicity, but the lower toxicity and successful mice model work must of caused a dramatic change in their opinion of this class of compounds. I expect dramatic new data to be presented by MGI in April at the American Association for Cancer Research. (I hope for a complete review of the Phase I trails including the current patients) richard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next